These are stressful times. If you would like to contact a social worker, psychologist or child life specialist for information on community referrals or coping resources, you can call 312.227.4118 and leave a message. Your call will be returned within 24 hours, Monday through Friday. Non-urgent questions only. For emergencies, call 911.
For information about telemedicine appointments, click here.
For information on Novel Coronavirus (COVID-19), click here.
Para obtener información sobre el COVID-19 en español, haga clic aquí.
Here at Lurie Children’s, our research team works tirelessly to bring our patients and families an abundance of clinical research opportunities, in a mission to discover new cures, every day. Our multidisciplinary team of physician-scientists conduct various research projects to help promote patient care and better educate families. We participate in studies funded by the National Institute of Health (NIH), pharmaceutical companies and our own investigator-initiated studies. We hope our research efforts will improve treatment for children with epilepsy.
Our current focus is in precision medicine, which strives to determine optimal personalized treatment methods based on genetic testing results. We hope to achieve the same success as with our existing studies, which will help our patients tremendously.
Description: This study is an assessment of electroencephalograms of children with Lennox-Gastaut Syndrome, treated at Lurie Children's. The goal of this study is to identify patterns in the EEG that could lead to earlier diagnoses in the future.
GWEP 1415- An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes
GWEP 1521- A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled focal seizures.
Description: The purpose of this study is to learn more about the best way to treat children with West syndrome. This study seeks to understand Cosyntropin, a new form of a commonly used drug to treat infantile spasms. Cosyntropin will be compared with vigabatrin, another commonly used drug to treat infantile spasms. We hope to understand if Cosyntropin alone or used in combination with vigabatrin works better than just vigabatrin alone.
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies
Description: Center for SUDEP Research (CSR) is the second Center Without Walls for collaborative research in the Epilepsies. This milestone-driven collaboration brings together extensive and diverse expertise to tackle SUDEP and will identify patients who are at higher risk of SUDEP, enabling further appropriate intervention and prevention of SUDEP in that specific population.
Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)
A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome